文献速递核素与放射性配体治疗肿瘤 PET/CT

靶向mGluR1的两种新型小分子放射性药物131I-IITM与211At-AITM

131I-IITM and 211At-AITM: Two Novel Small-Molecule Radiopharmaceuticals Targeting Oncoprotein Metabotropic Glutamate Receptor 1.
PubMed 文献 · J Nucl Med · 2019-08-26

本研究开发了靶向黑色素瘤异位代谢型谷氨酸受体1(mGluR1)的两种放射性药物131I-IITM和211At-AITM,在mGluR1表达的B16F10黑色素瘤细胞及荷瘤小鼠中评估疗效与安全性。两种药物放射化学纯度均大于99%,均可显著抑制肿瘤生长(分别61.00%和95.68%),其中211At-AITM疗效更强且毒性可忽略。

要点

  • 131I-IITM与211At-AITM放射化学纯度均大于99%。
  • 两者在靶向黑色素瘤中最大摄取分别为4.66%±0.70和7.68%±0.71 %ID/g。
  • 211At-AITM较131I-IITM展现出更强疗效且毒性可忽略。

核心结论

  • 无毒的131I-IITM和211At-AITM是靶向癌蛋白mGluR1用于黑色素瘤治疗的高精度TRT药物。

研究设计与样本

  • 通过锡基前体与131I-NaI或211At在氧化剂存在下反应合成131I-IITM和211At-AITM。
  • 使用表达mGluR1的B16F10黑色素瘤细胞及荷瘤小鼠研究两种药物的疗效与安全性。

主要发现

  • 131I-IITM和211At-AITM放射化学产率分别为42.7%±10.4%和45.7%±6.5%,放射化学纯度均大于99%。
  • 131I-IITM和211At-AITM在靶向黑色素瘤中最大摄取分别为4.66%±0.70和7.68%±0.71 %ID/g,静脉注射后从非靶器官快速清除。
  • 与对照组相比,两种药物均显著抑制黑色素瘤生长,抑制率分别为61.00%和95.68%。
  • 在黑色素瘤模型中,211At-AITM疗效显著更强且毒性可忽略。

临床怎么用

  • 131I-IITM和211At-AITM可用于靶向mGluR1的黑色素瘤精准放射性核素治疗。
  • 211At-AITM在黑色素瘤模型中显示更强疗效且毒性可忽略,具备进一步开发潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted radionuclide therapy (TRT) targeting oncoproteins facilitates the delivery of therapeutic radionuclides to tumor tissues with high precision. Herein, we developed 2 new radiopharmaceuticals, 4-131I-iodo- and 4-211At-astato-N-[4-(6-(isopropylamino)pyridine-4-yl)-1,3-thiazol-2-yl]-N-methylbenzamide (131I-IITM and 211At-AITM), targeting the ectopic metabotropic glutamate receptor 1 (mGluR1) in melanomas for TRT studies. Methods:131I-IITM and 211At-AITM were synthesized by reacting a stannyl precursor with 131I-NaI and 211At in the presence of an oxidizing agent. The therapeutic efficacy and safety of the 2 radiopharmaceuticals were investigated using mGluR1-expressing B16F10 melanoma cells and melanoma-bearing mice. Results:131I-IITM and 211At-AITM were obtained with a radiochemical purity of greater than 99% and radiochemical yields of 42.7% ± 10.4% and 45.7% ± 6.5%, respectively, based on the total radioactivity of used radionuclides. 131I-IITM and 211At-AITM exhibited a maximum uptake of 4.66% ± 0.70 and 7.68% ± 0.71 percentage injected dose per gram (%ID/g) in the targeted melanomas, respectively, and were rapidly cleared from nontarget organs after intravenous injection. Both agents markedly inhibited melanoma growth compared with the controls (61.00% and 95.68%, respectively). In the melanoma model, considerably greater therapeutic efficacy with negligible toxicity was observed using 211At-AITM. Conclusion: The nontoxic radiopharmaceuticals 131I-IITM and 211At-AITM are useful high-precision TRT agents that can be used to target the oncoprotein mGluR1 for melanoma therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xie L, Hanyu M, Fujinaga M, et al. 131I-IITM and 211At-AITM: Two Novel Small-Molecule Radiopharmaceuticals Targeting Oncoprotein Metabotropic Glutamate Receptor 1. J Nucl Med. 2019. PMID: 31451486. doi:10.2967/jnumed.119.230946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。